Cell factories: making vaccine production more efficient and safer
In the production of vaccines, monoclonal antibodies and biopharmaceuticals, large-scale culture of wall-adherent cells is a key link. While traditional rotary flask culture methods face large space occupation and high risk of contamination, cell factories are becoming the preferred solution for modern biopharmaceutical companies with their innovative multi-layer design and closed piping system.
In the production of vaccines, monoclonal antibodies and biopharmaceuticals, large-scale culture of wall-adherent cells is a key link. While traditional rotary flask culture methods face large space occupation and high risk of contamination, cell factories are becoming the preferred solution for modern biopharmaceutical companies with their innovative multi-layer design and closed piping system.
Why choose cell factory?
1. 80%+ increase in space utilization rate, directly reducing plant costs
The modular design from 1 to 40 layers allows for capacity expansion by simply adding more layers without the need for additional space for culture equipment.
Compared with traditional rotary bottles, the plant occupancy can be reduced by more than 60% under the same output, which significantly saves the enterprise's investment in infrastructure and operation and maintenance.
2. Closed piping system reduces the risk of contamination by more than 50%.
Standard with aseptic transfer components (CPC connector, three-way piping, etc.), support multiple units in series to form a completely closed environment.
Avoiding the introduction of contamination by manual operation, especially suitable for continuous production under GMP environment.
3. Cost-effective double enhancement
Reduced plant space requirements → reduce QC environment maintenance costs
Reduced contamination rate → reduce batch scrap loss and repeat verification costs
Industry Application Scenarios
✓ Vaccine production: high-density culture of vero cells and MRC-5 cells.
✓ Monoclonal antibody preparation: large-scale expansion of CHO cells
✓ Gene therapy: stem cell vector production
Currently, many vaccine companies around the world have adopted cell factories as an alternative to the transfer vial process. Its core value lies in the fact that it carries more capacity in less space and guarantees higher compliance with lower contamination rates - the ultimate demand for scale-up of biopharmaceutical production.